More than 10% of the settlements were so-called “reverse payment settlements” which limited the entry to the market of the generic medicines and provided for payments from the originator to the generic companies.
Üle 10 % neist kokkulepetest piirasid geneeriliste ravimite turulepääsu ja nägid vastutasuks ette maksed originaalravimeid tootvatelt ettevõtetelt geneeriliste ravimite tootjatele (nn pöördmakse kokkulepped).